促红细胞生成素治疗非小细胞肺癌化疗所致贫血的临床研究

目的评价促红细胞生长素(EPO)治疗非小细胞肺癌(NSCLC)患者化疗所致贫血的临床疗效及副反应。方法64例NSCLC患者分成观察组34例和对照组30例,观察组化疗同时皮下注射EPO,剂量为150 u.kg-1体重,每周3次;对照组化疗同时给予利血君口服,观察两组的治疗效果和不良反应。结果治疗2周后观察组和对照组血红蛋白浓度、红细胞压积、红细胞总数均较治疗前显著降低(P<0.01)。治疗4周起观察组血红蛋白浓度、红细胞压积、红细胞总数均明显上升(P<0.01),且高于对照组同期水平(P<0.01)。治疗结束后观察组血红蛋白浓度、红细胞压积、红细胞总数均较治疗前显著增加(P<0.01)。结论EPO对非小细胞肺癌采用以顺铂为主联合化疗方案所致贫血有肯定的疗效。

Clinical analysis of erythropoietin therapy for patients with non-small cell lung cancer complicated by anemia induced by chemotherapy

Objective To evaluate the efficacy and toxicity of erythropietin(EPO) in the treatment of non-small cell lung cancer(NSCLC) patients with chemotherapy-related anemia.Methods Sixty-fore NSCLC patients with anemia were divided non-randomly into a treatment group,receiving chemotherapy concurrent with EPO(150 IU·kg~(1)),3 times every week;and a control group,receiving chemotherapy concurrent with leucoson.The efficacy and toxicity were compared.Results From the fourth week after therapy,the Hb,HCT and RBC of the EPO treatment group was significantly increased compared with those before treatment(P<0.01)and control group(P<0.01).Conclusion The effect of EPO for anemic patients with NSCLC on cisplatin-based combination chemotheraphy is definitely positive.